Meloxicam G.L. (Meloxicam)

Meloxicam works by preferentially inhibiting the cyclooxygenase‑2 (COX‑2) enzyme, which reduces the production of prostaglandins that drive inflammation, pain, and fever. By targeting COX‑2 more than COX‑1, it provides anti‑inflammatory and analgesic effects while preserving some protective functions of COX‑1 in the stomach and platelets.

The appropriate dose of Meloxicam G.L. is determined by the prescribing healthcare professional based on the patient’s specific condition, severity of symptoms, renal and hepatic function, and any concomitant medications. Dosing recommendations are individualized, and patients should follow the prescriber’s instructions without self‑adjusting the amount.

Meloxicam is classified as pregnancy category C, indicating that risk cannot be ruled out and it should be used only if the potential benefit justifies the potential risk to the fetus. It is excreted in breast milk, so caution is advised for nursing mothers, and alternative therapies may be considered.

To order Meloxicam G.L., submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The sales team then replies with pricing, availability, shipping details (including cold‑chain if required) and the necessary import documentation.

Meloxicam offers a longer half‑life and preferential COX‑2 inhibition compared with many non‑selective NSAIDs, which can translate into once‑daily dosing and potentially lower gastrointestinal risk. However, it shares class‑related cautions such as cardiovascular and renal considerations, and individual patient factors determine whether it is preferred over alternatives like ibuprofen or naproxen.

Meloxicam G.L. should be stored at refrigerated temperatures between 2 °C and 8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Maintaining the cold chain preserves product stability and potency.

Meloxicam G.L. is administered by intramuscular injection, typically into a large muscle such as the gluteus maximus. The injection is performed by a qualified healthcare professional using aseptic technique. The exact injection site, volume, and frequency are determined by the prescribing clinician.

Serious risks include gastrointestinal ulceration or bleeding, severe skin reactions such as Stevens‑Johnson syndrome, and renal impairment that can lead to acute kidney injury. Cardiovascular events like myocardial infarction or stroke may also occur, particularly in patients with existing heart disease. Prompt medical attention is required if any of these events are suspected.

Meloxicam G.L. should be avoided in patients with known hypersensitivity to meloxicam or other NSAIDs, those with active gastrointestinal ulceration, severe renal or hepatic impairment, and in the third trimester of pregnancy. Caution is also advised for individuals with uncontrolled hypertension, heart failure, or a history of cardiovascular disease.